{"protocolSection":{"identificationModule":{"nctId":"NCT00663416","orgStudyIdInfo":{"id":"NTx™-265-CP-201-IS (CA)"},"organization":{"fullName":"Stem Cell Therapeutics Corp.","class":"INDUSTRY"},"briefTitle":"REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients","officialTitle":"A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)","acronym":"REGENESIS"},"statusModule":{"statusVerifiedDate":"2009-08","overallStatus":"TERMINATED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2008-10","type":"ESTIMATED"},"completionDateStruct":{"date":"2009-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2008-04-18","studyFirstSubmitQcDate":"2008-04-21","studyFirstPostDateStruct":{"date":"2008-04-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2009-08-10","lastUpdatePostDateStruct":{"date":"2009-08-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Alan Moore / President & Chief Executive Officer","oldOrganization":"Stem Cell Therapeutics Corp."},"leadSponsor":{"name":"Stem Cell Therapeutics Corp.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.\n\nSecondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":134,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: NTx™-265: rhCG, then rEPO"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Saline placebo"]}],"interventions":[{"type":"DRUG","name":"NTx™-265: rhCG, then rEPO","description":"* rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then\n* rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["1"],"otherNames":["Ovidrel","Eprex"]},{"type":"DRUG","name":"Saline placebo","description":"* Saline SC, on Day 1, 3, and 5 of study participation, then\n* Saline IV, on Day 7, 8, and 9 of study participation","armGroupLabels":["2"],"otherNames":["Sodium Chloride 0.9%"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Modified Rankin Score (mRS)","timeFrame":"Day 90"},{"measure":"NIHSS response","timeFrame":"Day 90"}],"secondaryOutcomes":[{"measure":"NIHSS","timeFrame":"Day 90"},{"measure":"mRS","timeFrame":"Day 90"},{"measure":"Barthel Index","timeFrame":"Day 90"},{"measure":"Action Research Arm Test","timeFrame":"Day 90"},{"measure":"Gait Velocity Test","timeFrame":"Day 90"},{"measure":"Boston Naming Test","timeFrame":"Day 90"},{"measure":"Line Cancellation Test","timeFrame":"Day 90"},{"measure":"Trails A & B Test","timeFrame":"Day 90"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18-85.\n* NIHSS score 6-24 within 24-48 hours after stroke onset and enrolment.\n* Stroke is ischemic in origin, supratentorial, and radiologically confirmed (CT scan or diagnostic MRI) prior to enrolment.\n* Patient is 24-48 hours from time of stroke onset when the first dose of NTxTM-265 therapy is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when patient was last seen or was self-reported to be normal.\n* Reasonable expectation of availability to receive the full 9 day NTxTM-265 course of therapy, and to be available for subsequent follow-up visits.\n* Reasonable expectation that patient will receive standard post-stroke physical, occupational and speech therapy as indicated.\n* Female patient is either:\n\n  1. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral oophorectomy or hysterectomy) or\n  2. If of childbearing potential, agrees to use two of the following effective separate forms of contraception throughout the study, up to and including the follow-up visits:\n\n     * Condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (e.g., implants, injectables, combined oral, etc) OR\n     * A vasectomised partner OR\n     * Abstinence\n\nExclusion Criteria\n\n* Patients presenting with lacunar, hemorrhagic and/or brain stem stroke.\n* Patients who have received thrombolytic treatment with tPA following the index stroke.\n* Patients classified as comatose, defined as a patient who required repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (NIHSS 1A score must be \\<2)\n* Women who have tested positive for pregnancy, or are breast-feeding or are not using a highly effective method of birth control that can be maintained for the duration of the study.\n* Serum hemoglobin \\> 16 g/dL (males) or \\> 14 g/dL (females); or platelet count \\> 400,000/mm3.\n* Advanced liver,kidney, cardiac or pulmonary disease; the former will be operationally defined using NCI Toxicity Criteria (Grade 2 or higher)\n* Serum bilirubin \\> 1.5 x upper limit of normal (ULN).\n* Alkaline phosphatase \\> 2.5 x ULN.\n* AST\\>2.5xULN.\n* ALT \\> 2.5 x ULN.\n* Creatinine \\> 2.0 x ULN.\n* Patients with known and documented transferrin saturation \\< 20%.\n* Patients with known and documented ferritin \\< 100 ng/mL.\n* Patients with known and documented elevated PSA levels, or a PSA level of ≥ 4 ng/mL at screening.\n* Patients with a known or current history of abnormal hypercoagulability parameters , including known cardiolipin/antiphospholipid antibody syndrome.\n* Expected survival \\< 1 year.\n* Allergy or other contraindication to hCG including:\n\n  1. Prior hypersensitivity to hCG preparations or one of their excipients.\n  2. Primary ovarian failure.\n  3. Uncontrolled thyroid or adrenal dysfunction.\n  4. An uncontrolled organic intracranial lesion such as a pituitary tumor.\n  5. Abnormal uterine bleeding of undetermined origin.\n  6. Ovarian cyst or ovarian enlargement of undetermined origin.\n  7. Sex hormone dependent tumors of the reproductive organs, accessory sex glands, and breasts.\n* Allergy or other contraindication to epoetin alfa:\n\n  1. Who developed pure red cell aplasia following treatment with any erythropoiesis regulating hormones\n  2. With uncontrolled hypertension\n  3. With known hypersensitivity to mammalian cell-derived products, albumin (human) or any component of the product\n  4. Who for any reason cannot receive adequate antithrombotic treatment\n* A known diagnosis of cancer (except non-malignant skin cancer).\n* Uncontrolled hypertension, defined in the context of acute stroke as blood pressure persistently above 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive therapy.\n* Use of either hCG or epoetin alfa within the previous 90 days.\n* Any condition known to elevate hCG, active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor.\n* Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS) ≥ 2.\n* Any patients living in a nursing home or supervised living center. Patients must be historically fully independent in all activities of daily living including banking, shopping, cooking, toileting, showering and dressing.\n* Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial.\n* With the exception of the qualifying stroke, any other stroke within the previous 6 months.\n* Patients who cannot take anti-platelet therapy for the duration of the study.\n* Patients who cannot take low molecular weight or unfractionated heparin during hospitalization.\n* Pre-existing and active major psychiatric or other chronic neurological disease.\n* Consume, on average, greater than 14 alcoholic drinks per week, or have a history of substance abuse or dependency within 12 months prior to the study.\n* Currently participating in another investigational study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Michael D Hill, MD","affiliation":"Department of Clinical Neurosciences, University of Calgary","role":"PRINCIPAL_INVESTIGATOR"},{"name":"Steven C Cramer, MD","affiliation":"Department of Neurology, University of Califonia, Irvine Medical Center","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Department of Clinical Neurosciences, Univeristy of Calgary","city":"Calgary","state":"Alberta","zip":"T2N 2T9","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Walter Mackenzie Health Sciences Centre","city":"Edmonton","state":"Alberta","zip":"T6G 2B7","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Grey Nuns Community Hospital","city":"Edmonton","state":"Alberta","zip":"T6L 5X3","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Chinook Regional Hospital","city":"Lethbridge","state":"Alberta","zip":"T1J 1W5","country":"Canada","geoPoint":{"lat":49.69999,"lon":-112.81856}},{"facility":"Penticton Regional Hospital","city":"Penticton","state":"British Columbia","zip":"V2A 3G6","country":"Canada","geoPoint":{"lat":49.48062,"lon":-119.58584}},{"facility":"Vancouver General Hospital","city":"Vancouver","state":"British Columbia","zip":"V5Z 1M9","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Vancouver Island Health Research Centre","city":"Victoria","state":"British Columbia","zip":"V8R 1J8","country":"Canada","geoPoint":{"lat":48.43294,"lon":-123.3693}},{"facility":"Brandon Regional Health Centre","city":"Brandon","state":"Manitoba","zip":"R7A 2B3","country":"Canada","geoPoint":{"lat":49.84692,"lon":-99.95306}},{"facility":"Queen Elizabeth II Health Sciences Centre","city":"Halifax","state":"Nova Scotia","zip":"B3H 3A7","country":"Canada","geoPoint":{"lat":44.64533,"lon":-63.57239}},{"facility":"McMaster Clinic","city":"Hamilton","state":"Ontario","zip":"L8L 2X2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Trillium Health Centre","city":"Mississauga","state":"Ontario","zip":"L5B 1B8","country":"Canada","geoPoint":{"lat":43.5789,"lon":-79.6583}},{"facility":"Thunder Bay Regional Health Sciences Centre","city":"Thunder Bay","state":"Ontario","zip":"P7B 6V4","country":"Canada","geoPoint":{"lat":48.38202,"lon":-89.25018}},{"facility":"Division of Neurology , Sunnybrook Health Sciences Centre","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Department of Neurology, St. Michael's Hospital","city":"Toronto","state":"Ontario","zip":"M5B 1W8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"University Health Network","city":"Toronto","state":"Ontario","zip":"M5T 2S8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Montreal Neurological Institute","city":"Montreal","state":"Quebec","zip":"H3A 2B4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Department of Neurology, Care Hospital","city":"Hyderabad","state":"Andhra Pradesh","zip":"500001","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Krishna Institute of Medical Sciences","city":"Hyderabad","state":"Andhra Pradesh","zip":"500003","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Department of Neurology, Apollo Hospitals","city":"Hyderabad","state":"Andhra Pradesh","zip":"500033","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Department of Neurology, Nizam's Institute of Medical Science","city":"Hyderabad","state":"Andhra Pradesh","zip":"500082","country":"India","geoPoint":{"lat":17.38405,"lon":78.45636}},{"facility":"Max Super Speciality Hospital","city":"New Delhi","state":"Delhi","zip":"110017","country":"India","geoPoint":{"lat":28.63576,"lon":77.22445}},{"facility":"M S Ramaiah Memorial Hospital","city":"Bangalore","state":"Karnataka","zip":"560054","country":"India","geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Christian Medical College & Hospital","city":"Ludhiana","state":"Punjab","zip":"141008","country":"India","geoPoint":{"lat":30.91204,"lon":75.85379}},{"facility":"Department of Neurology, Christian Medical College","city":"Vellore","state":"Tamilnadu","zip":"632004","country":"India","geoPoint":{"lat":12.9184,"lon":79.13255}},{"facility":"AMRI Hospital","city":"Kolkata","state":"West Bengal","zip":"700029","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}},{"facility":"Department of Neurology, B.P.Poddar Hospital & Medical Research Ltd","city":"Kolkata","state":"West Bengal","zip":"700053","country":"India","geoPoint":{"lat":22.56263,"lon":88.36304}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M314","name":"Epoetin Alfa","relevance":"LOW"},{"id":"M8858","name":"Chorionic Gonadotropin","relevance":"LOW"}],"browseBranches":[{"abbrev":"Hemat","name":"Hematinics"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Repr","name":"Reproductive Control Agents"}]}},"hasResults":false}